Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade

Human Reproduction

Volumn 22, Issue 8, 2007, Pages 2196-2201

  Vieira, Carol Sales ^a   Ferriani, R A ^a   Garcia, A A ^a   Pintao M C ^a   Azevedo, G D ^b   Gomes, M K O ^a   Silva de Sa M F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Coagulation; Contraception; Etonogestrel; Haemostasis; Progestogens

Indexed keywords

ACTIVATED PROTEIN C; ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; D DIMER; ETONOGESTREL; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN S; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; VON WILLEBRAND FACTOR;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; FEMALE; FIBRINOGEN BLOOD LEVEL; FRIEDMAN TEST; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; LONGITUDINAL STUDY; NORMAL HUMAN; NORMAL VALUE; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; THROMBIN TIME;

EID: 34547801249     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dem153     Document Type: Article

References (34)

1. Bernauer S, Wehling M, Gerdes D, Falkenstein E. The human membrane progesterone receptor gene: Genomic structure and promoter analysis. DNA Seq 2001;12:13-25.
2. Boneu B, Bes G, Pelzer H, Sie P, Boccalon H. D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1 + 2: Diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost 1991;65:28-31.
3. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002;100 148-152.
4. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation 2007;115:840-845.
5. Conard J. Biological coagulation findings in third-generation oral contraceptives. Human Reprod Update 1999;5:672-680.
6. Conard J, Plu-Bureau G, Bahi N, Horellou MH, Pelissier C, Thalabard JC. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004;70:437-441.
7. Dahlbäck B. Blood coagulation. Lancet 2000;355:1627-1632.
8. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993;90 1004-1008.
9. Egberg N, van Beek A, Gunnervik C, Hulkko S, Hirvonen E, Larsson-Cohn U, Bennink HC. Effects on hemostatic system and liver function in relation to Implanon® and Norplant®. A prospective randomized clinical trial. Contraception 1998;58:93-98.
10. Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: Role of the glucocorticoid receptor. Circulation 2001;104:2826-2831.
11. Hinchliffe SA, Woods S, Gray S, Burt AD. Cellular distribution of androgen receptors in the liver. J Clin Pathol 1996;49 418-420.
12. Huber J. Pharmacokinetics of Implanon®. An integrated analysis. Contraception 1998;58:85S-90S.
13. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: Cohort and case-control analysis. BMJ 2000;321 1190-1195.
14. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 Ag of ethinyl estradiol. Contraception 2006;73:223-228.
15. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: Meta-analysis. BMJ 2001;323 131-134.
16. Kemmeren JM, Algra A., Meijers JC, Tans G, Bouma BN, Curvers J, Rosing J, Grobbee DE. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: A randomized trial. Blood 2004;103 927-933.
17. Lindqvist PG, Rosing J, Malmquist A, Hillarp A. Etonogestrel implant use is not related to hypercoagulable changes in anticoagulant system. J Thromb Haemost 2003;1:601-602.
18. Rivard GE, Brummel K, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thromboelastography. J Thromb Haemost 2005;3: 2039-2043.
19. Rosendaal FR, Vlieg AVH, Tanis BC, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003;1 1371-1380.
20. Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, van der Ploeg PM, Heijnen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997;97:233-238.
21. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003;36:428-432.
22. Schindler AE, Campagnoli C, Druckmannc R, Huber J, Pasqualini JR, Schweppef KW, Thijssen JHH. Classification and pharmacology of progestins. Maturitas 2003;46S1:S7-S16.
23. Stein PD, Hull RD, Patel KC, Olson RE, Ghali WA, Brant R, Biel RK, Bharadia V, Kalra NK. D-Dimer for the exclusion of acute venous thrombosis and pulmonary embolism. Ann Intern Med 2004; 140 589-602.
24. Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, Bouma BN, Buller HR, Rosing J. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000;84:15-21.
25. Tans G, van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J, Rosendaal FR. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003;122:465-470.
26. The Oral Contraceptive Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003;67:173-185.
27. Vasilakis C, Jick H, Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999;354 1610-1611.
28. Vieira CS, Ferriani RA, Garcia AA, Gomes MKO, Azevedo GD, Silva de Sá MF. Transitory reduction of platelet aggregation with the use of etonogestrel implant in healthy women. Thromb Haemost 2005;94 682-683.
29. de Visser MCH, Rosendaal FR, Bertina, RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271-1276.
30. de Visser MCH, van Hylckama Vlieg A, Tans G, Rosing J, Dahm AEA, Sandset PM, Rosendaal FR, Bertina RM. Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost 2005;3:1488-1494.
31. Winkler UH, Howie H, Bühler K, Korver T, Geurts TBP, Coelingh Bennink HJT. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 μg desogestrel or 30 μg levonorgestrel. Contraception 1998;57:385-392.
32. World Health Organization. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet 1995a;346:1575-1580.
33. World Heahh Organization. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995b;346:1582-1588.
34. World Health Organization. Cardiovascular Disease and Steroid Hormone Contraception. Report of a WHO Scientific group. WHO Technical Report Series 877. Geneva: World Health Organization, 1998.